Education
About Us
Working with TipRanks
Follow Us
Chugai Pharmaceutical Co Ltd (CHGCF)
OTHER OTC:CHGCF
RESEARCH TOOLSreports
CHGCF Stock Chart & Stats
Day’s Range― - ―
52-Week Range$28.60 - $55.39
Previous CloseN/A
Volume618.00
Average Volume (3M)4.04K
Market Cap
$72.46B
Enterprise Value$10.53T
Total Cash (Recent Filing)¥101.14B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)26.7
Beta0.61
Next Earnings
Apr 24, 2025EPS Estimate
0.35Next Dividend Ex-Date
Jun 27, 2025Dividend Yield1.41%
Share Statistics
EPS (TTM)0.39
Shares Outstanding1,679,057,600
10 Day Avg. Volume3,345
30 Day Avg. Volume4,039
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4.81
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$51.13Price Target Upside-13.99% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Chugai Pharmaceutical Co News
PremiumCompany Announcements
Chugai Pharmaceutical Adjusts Treasury Share Disposal Plan
PremiumCompany Announcements
Chugai Highlights Eli Lilly’s Promising Phase 3 Results for Orforglipron
PremiumCompany Announcements
Chugai Pharmaceutical Considers Investment Unit Reduction
PremiumCompany Announcements
Chugai Pharmaceutical’s Earnings Call: Record Performance Amid ChallengesPremiumCompany Announcements
Chugai Pharmaceutical Reports Record 2024 Financial Results---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
4.43% Mutual Funds
0.08% Other Institutional Investors
91.46% Public Companies and
Individual Investors
CHGCF FAQ
What was Chugai Pharmaceutical Co Ltd’s price range in the past 12 months?
Chugai Pharmaceutical Co Ltd lowest stock price was $28.60 and its highest was $55.39 in the past 12 months.
What is Chugai Pharmaceutical Co Ltd’s market cap?
Chugai Pharmaceutical Co Ltd’s market cap is $72.46B.
When is Chugai Pharmaceutical Co Ltd’s upcoming earnings report date?
Chugai Pharmaceutical Co Ltd’s upcoming earnings report date is Apr 24, 2025 which is yesterday.
How were Chugai Pharmaceutical Co Ltd’s earnings last quarter?
Chugai Pharmaceutical Co Ltd released its earnings results on Jan 30, 2025. The company reported $0.392 earnings per share for the quarter, missing the consensus estimate of $0.416 by -$0.024.
Is Chugai Pharmaceutical Co Ltd overvalued?
According to Wall Street analysts Chugai Pharmaceutical Co Ltd’s price is currently Overvalued.
Does Chugai Pharmaceutical Co Ltd pay dividends?
Chugai Pharmaceutical Co Ltd pays a Annually dividend of $0.529 which represents an annual dividend yield of 1.41%. See more information on Chugai Pharmaceutical Co Ltd dividends here
What is Chugai Pharmaceutical Co Ltd’s EPS estimate?
Chugai Pharmaceutical Co Ltd’s EPS estimate is 0.35.
How many shares outstanding does Chugai Pharmaceutical Co Ltd have?
Chugai Pharmaceutical Co Ltd has 1,679,057,600 shares outstanding.
What happened to Chugai Pharmaceutical Co Ltd’s price movement after its last earnings report?
Chugai Pharmaceutical Co Ltd reported an EPS of $0.392 in its last earnings report, missing expectations of $0.416. Following the earnings report the stock price went down -16.796%.
Which hedge fund is a major shareholder of Chugai Pharmaceutical Co Ltd?
Currently, no hedge funds are holding shares in CHGCF
---
Company Description
Chugai Pharmaceutical Co Ltd
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; osteoporosis, including Actemra, Edirol, and Bonviva; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group; and collaboration and joint research with academia. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.
---
CHGCF Company Deck
---
CHGCF Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted record-breaking financial results and significant overseas sales growth, coupled with an increase in dividends, showcasing the company's strong performance. However, challenges such as the decline in domestic sales, project discontinuations, and potential biosimilar competition were noted.Read More>---
CHGCF Stock 12 Month Forecast
Average Price Target
$51.13
▼(-13.99% Downside)
Technical Analysis
Astellas Pharma
―
Sumitomo Dainippon Pharma Co
―
Eisai Co
―
Shionogi & Co
―
Takeda Pharmaceutical Co
―
Best Analysts Covering CHGCF
1 Year
1 Year Success Rate
2/2 ratings generated profit
1 Year Average Return
+31.30%
reiterated a buy rating 5 months ago
Copying Seiji Wakao's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +31.30% per trade.
---